Head-to-head evidence
GK1-399 (formerly TTP399) vs SY-004
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: Glucokinase · full Type 2 Diabetes pipeline
GK1-399 (formerly TTP399)
Developed by vTv Therapeutics
NCT01474083 · Phase 1/2 · completed
The study was randomized, quadruple-blind, and placebo-controlled, with 248 participants across three GK1-399 dose groups and a placebo group. Its primary endpoint was a pharmacokinetic measure, a surrogate rather than a clinical outcome, and no primary endpoint results are posted.
SY-004
Developed by Suzhou Yabao Pharmaceutical
NCT04217291 · Phase 2 · completed
The trial was randomized, quadruple-blind, placebo-controlled, and enrolled 200 participants, but its primary endpoint was the surrogate measure of change in HbA1c rather than a hard clinical outcome. Because the registry does not report whether the primary comparison was favorable or statistically significant, the evidence is limited to a moderate grade.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: GK1-399 (formerly TTP399)'s landscape · SY-004's landscape